

S4. Characteristics of systematic review protocols identified in PROSPERO for prevention of COVID-19

Table 1 Characteristics of systematic review protocols identified in PROSPERO for prevention of COVID-19

Corresponding author	Country of affiliation of the review ^a	Review type	Population	Intervention	Outcomes	Study type included	Registration date	Anticipated completion date	Link ^b	Publication (date of publication)
Public health interventions (n=20)										
Ahmed	USA	SR, MA	persons working in non-healthcare or non-school settings (general population)	workplace Non-pharmaceutical measures	COVID-19 incidence, hospitalizations, COVID-19 mortality	RCT, NRSI, MS	04/05/2020	31/07/2020	182660	no
Ayouni	Tunisia	SR	general population	PHIs	effectiveness of mitigation of the spread of COVID-19	RCT, NRSI	30/06/2020	17/08/2020	196018	no
Cuadrado	Chile	living SR	school population	school practices to promote social distancing	all-cause/COVID-19 mortality, COVID-19 infection rate, reproduction number	RCT, NRSI, MS	21/04/2020	17/05/2020	180701	no
Delgrange	UK, England	rapid SR	high-income countries or economies (general population)	PHIs	mortality, COVID-19 incidence, COVID-19 reproduction number,	n.r.	19/05/2020	31/07/2020	183989	no
Elchall	Cochrane France	living SR, MA, NMA	high risk patients, close contacts of COVID-19 patients, healthcare workers, healthy volunteers (mixed population)	vaccination, prophylactic interventions, PPE, movement control strategies	COVID-19 incidence, hospital or ICU admissions or death, all-cause mortality, clinical efficacy	RCT, NRSI	28/04/2020	31/12/2021	182600	no
Frazer	UK, Ireland	SR	adults in long term care facilities (residents, employees, visitors) (high risk population)	any intervention to reduce COVID-19 transmission	COVID-19 morbidity, symptoms, mortality	any type	02/07/2020	31/08/2020	191569	yes, preprint (03/11/2020)
Fuentealba-Torres	Chile	rapid SR	countries in COVID-19 pandemic (general population)	quarantine restrictions	COVID-19 incidence, prevalence, mortality	NRSI, MS	05/05/2020	31/01/2021	183701	no
Iezadi	USA	SR, realist review, MA	general population	PHIs	COVID-19 incidence, basic reproduction number, mortality	NRSI	20/05/2020	28/02/2021	186855	no
Juneau	Canada	SR	general population	contact tracing	COVID-19 transmission	RCT, NRSI, MS	14/07/2020	13/08/2020	198462	yes, preprint (25/07/2020)
Khatib	India	rapid SR, MA	individuals at risk for COVID-19 (most likely high risk population)	WASH (Water, sanitation and Hygiene) interventions	COVID-19 incidence, hospitalisations, COVID-19 mortality, safety	NRSI, MS	16/04/2020	11/05/2020	179663	no

Li	China	SR, MA	people at risk of infection from COVID-19, MERS or SARS (high risk population)	physical interventions (PI, e.g., hand hygiene, PPE, isolation, social distancing)	mortality, COVID-19 incidence and severity, hospital admissions, safety	any type	15/04/2020	15/08/2020	178638	no
Mbakaya	Malawi	SR	any community setting (workplace, market, school settings, family, neighbourhood) (general population)	any community-based measures to prevent COVID-19	COVID-19 incidence, transmission	NRSI, MS	18/08/2020	30/10/2020	204984	yes, preprint (30/10/2020)
Milanese	Australia	rapid SR	general population	screening tools	COVID-19 infections	NRSI, MS	21/08/2020	15/10/2020	205274	no
Oliveira	Brazil	SR	general population	any intervention (based on health promotion)	effectiveness (universal health and social protection coverage)	RCT, NRSI	20/04/2020	30/06/2020	180066	no
Pearce-Smith	Public Health England, UK	rapid SR	persons in school setting (children and staff)	school measures during COVID-19 pandemic (re-openings, limited closures, other control measures)	SARS-CoV-2 infection rate in children and staff, transmission of SARS-CoV-2 within school settings, COVID-19 outbreaks in schools	RCT, NRSI, MS	15/06/2020	24/07/2020	191867	yes, online document (09/04/2021)
Pintel Ramos	Brazil	SR	health care workers (high risk population)	recommendations for prevention (e.g., using PPE)	COVID-19 infections in healthcare workers	NRSI	12/08/2020	11/12/2020	190491	no
Schuneman	Canada	rapid SR	close contacts of COVID-19 patients (high risk population)	distance (1m+) with or without mask and/or eye protection	disease transmission, COVID-19 infection, acceptability, disease severity	any type	16/04/2020	28/04/2020	177047	yes, journal (01/06/2020), preprint (26/05/2020)
Shah	India	SR, MA	general population	PHIs	COVID-19 infection rate, recovery rate, mortality, rate of growth of cases	any type	20/04/2020	31/07/2020	180528	no
Silva	Brazil	SR	elderly (60+) in home care (high risk population)	measures to prevent COVID-19	COVID-19 prevalence	RCT, NRSI, QS	12/06/2020	28/05/2021	188952	no
Wangge	Indonesia	rapid SR	asymptomatic population in COVID-19 pandemic (general population)	mass screening	COVID-19 incidence, mortality, transmission (basic reproduction number), resource use	NRSI, MS	29/06/2020	06/07/2020	190546	yes, journal (18/12/2020)
Personal protective equipment (n=10)										
Al-Moraissi	Saudi Arabia	rapid SR	adult dental health care workers (high risk population)	enhanced PPE	effectiveness against COVID-19 infection	RCT NRSI	25/06/2020	30/09/2020	192912	yes, preprint (23/11/2020)
Conceição de Jesus	Brazil	SR, MA	healthcare workers assisting COVID-19 patients (high risk population)	PPE	COVID-19 infections in healthcare workers	RCT, NRSI	20/04/2020	31/12/2020	180264	yes, journal, but not included ^c (05/09/2020)
Ekwaro	Uganda	rapid SR	general population, healthcare workers in low- and middle	masks (medical or non-medical)	COVID-19 infections	RCT, NRSI	20/08/2020	30/11/2020	205136	no

			income countries (mixed population)							
Griswold	UK, England	rapid SR	healthcare workers in hospital setting during COVID-19 pandemic (esp. emergency neurosurgical care) (high risk population)	use of PPE, rapid testing, chest CT for patients	COVID-19 incidence	RCT, NRSI	30/07/2020	31/08/2020	198267	no
Gupta	India	SR	general population	face mask (any type)	COVID-19 transmission: contacts/secondary attack ratio	RCT, NRSI	06/05/2020	10/06/2020	183807	no
Kurniawan	Indonesia	SR	general population	face mask (any type)	COVID-19 infections, COVID-19 mortality	RCT, NRSI	11/05/2020	01/09/2020	184371	no
Ortiz-Muñoz	Chile	SR, MA	healthy population at risk of COVID-19, MERS, SARS (mixed population)	gloves (any type)	COVID-19 infections, hospitalizations, all-cause mortality, safety	RCT, NRSI	27/05/2020	29/06/2020	188674	yes, preprint (26/01/2021)
Schmölzer	International Liaison Committee on Resuscitation	SR, MA	healthcare workers attending deliveries (high risk population)	PPE	transmission of COVID-19 infection to healthcare workers, quality of neonatal resuscitation	RCT, NRSI	16/04/2020	05/05/2020	178250	no
Silveira	Brazil	SR, MA	healthcare workers assisting COVID-19 patients (high risk population)	techniques of using of PPE	COVID-19 infections in healthcare workers	RCT, NRSI	15/07/2020	30/11/2020	198631	no
Teoh	China	SR, MA	healthcare workers performing surgical, endoscopic and anaesthetic procedures on patients with COVID-19, SARS or MERS (high risk population)	use of PPE	transmission of SARS-CoV-2, SARS-CoV and MERS-CoV, risk of infection	RCT, NRSI	28/04/2020	24/05/2020	182298	no
Vaccination (n=9)										
Adhikari	Illinois, USA	SR, MA	adults (18+) with or without comorbidities (mixed population)	BCG vaccine	COVID-19 incidence and severity at 6 (9, 12) months	RCT	24/04/2020	31/05/2021	182122	no
Alhassane	France	SR, NMA	healthy adults (general population)	COVID-19 vaccine	COVID-19 incidence, immunogenicity, safety	RCT (phase I-III)	23/07/2020	31/08/2021	200012	no
Azhir	Canada	SR, MA, NMA	healthy adults (18-60) not previously infected (general population)	COVID-19 vaccine	all-cause mortality, COVID-19 incidence, safety	RCT, NRSI	26/08/2020	31/10/2021	204881	no
Baliga	India	SR, MA	health care workers with or without comorbidities (high risk population)	BCG vaccine	COVID-19 mortality, COVID 19 incidence and severity	RCT	08/06/2020	10/06/2021	189394	no

Henriques	Portugal	SR, MA	adults (18+) with or without comorbidities, healthcare professionals (mixed population)	BCG vaccine	COVID-19 incidence and severity	RCT, NRSI	02/06/2020	31/07/2021	188486	no
Kwasi Korang	Denmark	living SR, NMA, IPD-MA	people not previously infected (general population)	COVID-19 vaccine	all-cause mortality, COVID-19 incidence, safety	RCT	01/07/2020	01/06/2021	196492	no
Remón Torres	Peru	SR, MA	healthy adults (18+) not previously infected with SARS-CoV-2 (general population)	COVID-19 vaccine	COVID-19 incidence	RCT (phase III)	28/08/2020	31/01/2022	206390	no
Singh	India	SR, MA	healthy people without pre-exposure or infection with COVID-19 (general population)	BCG vaccine	COVID-19 mortality, COVID-19 incidence, safety	RCT, NRSI	18/08/2020	15/10/2020	204466	yes, preprint (28/10/2020)
Trunk	Switzerland	SR, MA	children and adults (0-80) (general population)	BCG vaccine, MCV, OPV, SPV, DTP vaccine	COVID-19 incidence and severity	RCT, NRSI	01/05/2020	30/06/2021	183428	no
Pharmaceutical interventions (n=4)										
Lenza	Brazil	SR, MA	adults (18+) with household or occupational exposure (high risk population)	CQ, HCQ	COVID-19 incidence and severity, hospitalisation, antibodies, mortality, clinical efficacy, safety	RCT, NRSI	10/07/2020	31/12/2020	197070	no
Meremikwu	Nigeria	SR, MA	peoples at high risk of exposure to COVID-19 (high risk population)	CQ, HCQ (+/- azithromycin or clarithromycin)	COVID-19 incidence and severity; safety	RCT, NRSI	02/06/2020	30/06/2020	184020	no
Quintanilla Sánchez	Mexico	SR, MA	asymptomatic adults (18+) with exposure to COVID-19 (high risk population)	CQ, HCQ	COVID-19 incidence, safety, hospitalisation	RCT, NRSI	14/04/2020	30/04/2021	177993	no
Singh	UK	SR, MA	people at risk of exposure or with exposure to SARS-CoV-2 (high risk population)	CQ, HCQ (+/- other treatments)	COVID-19 incidence and severity, infections in close contacts, antibodies, mortality, clinical efficacy, safety,	RCT	19/05/2020	08/06/2020	185220	yes, Cochrane review (12/02/2021)
Other interventions (n=4)										
El-Hajj Fuleihan	Lebanon	SR, MA	adults (18+) (general population)	vitamin D (supplementation, vitamin D deficiency)	COVID-19 seropositivity, risk of positive seroconversion to family members	RCT, NRSI	14/08/2020	12/11/2020	203960	yes, journal (24/03/2021)
Hernández Vásquez	Peru	SR	Individuals of all ages (healthy, pre-exposure, post-exposure to COVID-19, MERS or SARS) (mixed population)	chlorine dioxide, chlorine derivatives	clinical efficacy and safety	RCT, NRSI	27/07/2020	27/08/2020	200641	yes, journal (07/09/2020)
Wang	China	living SR, MA	asymptomatic people with/ without exposure (pre-/ post-exposure) to COVID-19 (mixed population)	Western medicine, TCM agents; each alone or in combination	COVID-19-free survival, COVID-19 incidence, hospitalization, mortality, safety	RCT, NRSI	08/06/2020	31/12/2021	190210	no

Xu	China	SR, NMA	hospital workers and laboratory technicians in high-risk virus laboratories (high risk population)	TCM (extracts from herbs)	COVID-19 infections, time and rate of disappearance of symptoms	RCT	20/04/2020	01/06/2021	179399	no
----	-------	---------	--	---------------------------	---	-----	------------	------------	------------------------	----

BCG=Bacillus Calmette-Guérin; COVID-19=Corona-Virus Disease 2019; CQ=Chloroquine; CT=Computer Tomography; DTP=Diphtheria-Tetanus-Pertussis; HCQ=Hydroxychloroquine; ICU=Intensive Care Unit; IPD=Individual Participant Data; MA=Meta-Analysis; MCV=Measles Containing Vaccine; MERS = Middle East Respiratory Syndrome; MS=Modelling Studies; NMA=Network Meta-Analysis; n.r.=not reported; NRSI=Non-Randomized Studies of Interventions including, cohort studies, case-control-studies, cross-sectional studies and case series/reports; OPV=Oral Polio Vaccine; PHI=Public Health Intervention; PPE=Personal Protective Equipment; QS=Qualitative Studies; RCT=Randomized Controlled Trials; SARS =Severe Acute Respiratory Syndrom; SPV=Smallpox Vaccine; SR=Systematic Review; TCM=Traditional Chinese Medicine.

^acountry of institutional affiliation of corresponding and/or first author

^bLink to the PROSPERO protocol: https://www.crd.york.ac.uk/prospéro/display_record.php?RecordID=>>Record-ID<<

^cPublication found, but population, intervention, outcomes did not meet our inclusion criteria.